Biosimilar developer Sandoz today announced the launch of its biosimilar adalimumab, Hyrimoz, in Spain. The biosimilar, referencing Humira, was authorized for sale in the European Union in July 2018.
Biosimilar developer Sandoz today announced the launch of its biosimilar adalimumab, Hyrimoz, in Spain. The biosimilar, referencing Humira, was authorized for sale in the European Union in July 2018.
The biosimilar is approved for all of the indications of the reference adalimumab, and is available in 40-mg doses for subcutaneous injection in either a syringe or prefilled pen.
"The debilitating effect that conditions such as rheumatoid arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis have on the individual is having an increasing impact on health systems throughout the world," said Joaquín Rodrigo Poch, general director of Sandoz Iberia, in a statement announcing the biosimilar’s launch. He added that the biosimilar will free up resources that can be directed to patient care and the sustainability of the healthcare system as a whole.
Containing healthcare spending is a major challenge that faces policy makers in all developed countries, and Spain is no exception. In fact, according to a 2017 paper, Spain’s spending on healthcare has long been growing faster than its national income.1 The nation’s aging population, high unemployment that limits the tax revenue that funds the system, and the rise of specialty medicines have put further pressure on the country to improve its system’s sustainability.
Yet according to a 2018 report from Medicines for Europe, pharmaceuticals now comprise 16.7% of total healthcare spending in Spain, and that figure saw a 9% decrease between 2008 and 2011 amid a push to reduce the prices of generic medicines.
The market entry of biosimilar adalimumab could help Spain to reduce its pharmaceutical spending further if the country is able to mirror the successes of its EU counterparts; in November 2018, the United Kingdom announced that adding biosimilar adalimumab to its National Health Service would allow the country to cut its spending on adalimumab by 75%.
While Hyrimoz is also approved in the United States, having earned FDA authorization in October 2018, the drug will not enter the US market before September 2023 per the terms of a patent dispute settlement between Sandoz and Humira maker AbbVie.
Reference
1. Avanzas P, Pascual I, Moris C. The great challenge of the public health system in Spain. J Thorac Dis. 2017;9(suppl 6):S430-S433. doi: 10.21037/jtd.2017.04.59.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.